Target Approaches
Kinases
Protein kinases represent a crucial family of enzymes that regulate a wide range of biological processes including differentiation, proliferation and metabolism. Due to their role in various diseases, they are key targets for therapeutic intervention. Accounting for roughly 30% of all drug discovery research endeavors, kinase inhibitors are at the forefront of not just cancer therapy development but also the treatment of a variety of other conditions such as inflammatory disorders, autoimmune diseases, neurological, metabolic and cardiac ailments. The domain of kinase drug discovery has advanced considerably, with the creation of selective allosteric inhibitors and activators that have become essential components in the design of kinase assays.
Jubilant Biosys offers comprehensive services in the development of kinase assays, including high-throughput screening and structure-activity relationship (SAR) support. Our custom-tailored screening platforms encompass a wide array of biochemical and cell based assays, designed to meet the specific needs of our clients in their pursuit of novel kinase therapeutics.
Assays & approaches
- Substrate conversion (Absorbance, Fluorescence).
- Substrate Phosphorylation (Fluoroscence, TRF, HTRF, AlphaLISA, ELISA).
- ATP conversion (ADP-Glo, Kinase-Glo).
- Kinase Binding (TR-FRET LanthaScreen).
- Phospho-protein analysis (Jess, In-cell western, Traditional Western blotting).
- Custom made phenotypic assays based on target biology.
Jubilant Biosys can support client projects at all stages of preclinical development ranging from protein production to preclinical candidate nomination. Our medicinal and computational chemists are experienced at designing compounds to target different classes of kinases with allosteric and covalent inhibitors. Medicinal chemistry strategies are driven by structure-based drug design using information provided by our in-house X-ray crystallographers.